Chordate Medical Holding AB (publ) ("Chordate", the "Company") announces that the European Patent Office intends to grant Chordate's patent application EP 17168265.1 from 2017. The patent application relates to further development of the Company's treatment technology for primarily chronic migraine, Kinetic Oscillation Stimulation, K.O.S.
“The aim of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company's intellectual property enables exclusivity in the market, which is a cornerstone of the shareholder value the company is building", says Anders Weilandt, CEO of Chordate Medical.
Chordate Medical holds approximately 71 patents across 26 countries and 9 patent families, covering various aspects of the company's treatment technologies. The granting of application EP 17168265.1 adds further patents to a growing portfolio that the company started to build in 2008.